Cargando…

Sulphoxythiocarbamates modify cysteine residues in HSP90 causing degradation of client proteins and inhibition of cancer cell proliferation

BACKGROUND: Heat shock protein 90 (HSP90) has a key role in the maintenance of the cellular proteostasis. However, HSP90 is also involved in stabilisation of oncogenic client proteins and facilitates oncogene addiction and cancer cell survival. The development of HSP90 inhibitors for cancer treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Y, Dayalan Naidu, S, Samarasinghe, K, Van Hecke, G C, Pheely, A, Boronina, T N, Cole, R N, Benjamin, I J, Cole, P A, Ahn, Y-H, Dinkova-Kostova, A T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3887302/ https://www.ncbi.nlm.nih.gov/pubmed/24322890 http://dx.doi.org/10.1038/bjc.2013.710

Ejemplares similares

Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma
por: Jin, L, et al.
Publicado: (2011)

KEAP1, a cysteine-based sensor and a drug target for the prevention and treatment of chronic disease
por: Dayalan Naidu, Sharadha, et al.
Publicado: (2020)

Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition
por: Xu, W, et al.
Publicado: (2007)

High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors
por: Engerud, H, et al.
Publicado: (2014)

Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin
por: Wu, X, et al.
Publicado: (2009)

Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease
por: Kang, B H, et al.
Publicado: (2011)

Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib
por: Courtin, Aurelie, et al.
Publicado: (2016)

Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction
por: Stingl, L, et al.
Publicado: (2010)

Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer
por: Lee, S J, et al.
Publicado: (2014)

Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity
por: Vinjamuri, S, et al.
Publicado: (2013)

The role of MMP-9 in the anti-angiogenic effect of secreted protein acidic and rich in cysteine
por: Bhoopathi, P, et al.
Publicado: (2010)

Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo
por: Gibert, B, et al.
Publicado: (2012)

γ-Glutamyl hydrolase modulation and folate influence chemosensitivity of cancer cells to 5-fluorouracil and methotrexate
por: Kim, S-E, et al.
Publicado: (2013)

Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines
por: Zaremba, T, et al.
Publicado: (2009)

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
por: Bray, J, et al.
Publicado: (2010)

The interaction between C35 and ΔNp73 promotes chemo-resistance in ovarian cancer cells
por: Leung, T H-Y, et al.
Publicado: (2013)

Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment
por: Takagi, K, et al.
Publicado: (2013)

Efficacy of gene therapy-delivered cytosine deaminase is determined by enzymatic activity but not expression
por: Dubois, L, et al.
Publicado: (2007)

Comparative drug screening in NUT midline carcinoma
por: Beesley, A H, et al.
Publicado: (2014)

Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma
por: Fujiwara-Okada, Y, et al.
Publicado: (2013)

CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma
por: Fukusumi, T, et al.
Publicado: (2014)

Regulation of focal adhesion turnover by ErbB signalling in invasive breast cancer cells
por: Xu, Y, et al.
Publicado: (2009)

γ-Tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways
por: Yap, W N, et al.
Publicado: (2008)

Biological significance of fluorine-18-α-methyltyrosine (FAMT) uptake on PET in patients with oesophageal cancer
por: Suzuki, S, et al.
Publicado: (2014)

ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer
por: Watanabe, T, et al.
Publicado: (2015)

Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma
por: Hirashima, K, et al.
Publicado: (2012)

Cytokeratins 18 and 8 are poor prognostic markers in patients with squamous cell carcinoma of the oesophagus
por: Makino, T, et al.
Publicado: (2009)

Acquired platinum resistance enhances tumour angiogenesis through angiotensin II type 1 receptor in bladder cancer
por: Tanaka, N, et al.
Publicado: (2011)

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states
por: Yoshida, T, et al.
Publicado: (2014)

Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer
por: Mochiki, E, et al.
Publicado: (2012)

Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases
por: Horimoto, Y, et al.
Publicado: (2015)

Characterisations of human prostate stem cells reveal deficiency in class I UGT enzymes as a novel mechanism for castration-resistant prostate cancer
por: Williamson, S C, et al.
Publicado: (2013)

EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy
por: Kumai, T, et al.
Publicado: (2013)

Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer
por: Kozakai, N, et al.
Publicado: (2012)

CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype
por: Helsby, N A, et al.
Publicado: (2008)

Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice
por: Edrei, Y, et al.
Publicado: (2012)

Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1
por: Akashi, Y, et al.
Publicado: (2014)

Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling
por: Wang, L-H, et al.
Publicado: (2014)

MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer
por: Hasegawa, S, et al.
Publicado: (2014)

Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer
por: Lee, H J, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pavdkuieb66css38i3f1d2rsbb